ADJUVANT HORMONE THERAPY ELIGIBILITY OF PREMENOPAUSAL WOMEN WITH ER+ BREAST CANCER
Adjuvant endocrine therapy of premenopausal patients with ER+ breast cancer typically consists in administration of tamoxifen for 5 years. However, in cases of high risk of disease recurrence there is a need to suppress (inhibit) function of the ovaries as the main generators of estrogen stimulating...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2017-06-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/1902 |